Boston Scientific Corporation (BSX)

Boston Scientific's stock has shown strong performance over the past six months. Strong Q3 2025 performance and raised outlook led to a 2.6% climb in shares. The cardiology unit was a significant driver of growth. Analyst endorsements and price target increases signaled confidence in the company's future growth. The acquisition of Nalu Medical aims to bolster its presence in the peripheral nerve stimulation market. An update on the IVUS CHIP UPP Registry was announced. Boston Scientific raised its annual profit forecast and trimmed its expectation for tariff-related costs.

The medical devices industry benefits from recurring revenue streams and an aging global population. Boston Scientific has reported steady quarterly demand for key cardiovascular devices, suggesting consistent demand throughout the year for its core products. Overall industry trends imply a generally stable demand environment for Boston Scientific's offerings.

Boston Scientific Corporation (BSX) is a global medical device company focused on minimally invasive technologies. It operates through three segments: Cardiovascular, Rhythm and Neuro, and MedSurg. The Cardiovascular segment includes Interventional Cardiology and Peripheral Interventions, addressing heart and vascular conditions. The Rhythm and Neuro segment focuses on Cardiac Rhythm Management, Electrophysiology, and Neuromodulation. The MedSurg segment includes Endoscopy, Urology, and Pelvic Health.

Boston Scientific operates in over 100 countries with regional headquarters in Europe, Asia Pacific, and Latin America. The United States is its largest region, representing 60.96% of its total revenue in fiscal year 2024, and experienced the highest revenue growth for the company in 2024, at +21.19%.

Boston Scientific focuses on corporate responsibility, advancing science, empowering people, and promoting a healthier planet. Recent news highlights the company's strong financial performance, product innovations, and strategic acquisitions, suggesting a positive market perception.

Institutional shareholders hold a significant portion of Boston Scientific Corp.'s shares, with approximately 89.07% of the shares. There were 2,909 funds or institutions reporting positions in Boston Scientific, an increase of 78 owners in the last quarter. Major institutional owners include Vanguard Total Stock Market Index Fund Investor Shares, Vanguard 500 Index Fund Investor Shares, Primecap Management, Bank Of America, and Wellington Management Group Llp.